In the MRL/lpr mouse model of SLE, exosome treatment reduced CD86 and increased CD206 expression in renal macrophages, along with lowered levels of pro-inflammatory cytokines (IFN-γ, IL-1β, IL-6) and elevated levels of anti-inflammatory cytokines (IL-10, TGF-β). This evidence concerns the gene IL6 and systemic lupus erythematosus.